BioCardia, Inc. · NASDAQ:BCDA
BioCardia — Investor Presentation (September 2025)
35 slides from BioCardia's investor presentation, September 2025
Slide 1: Corporate Presentation
Developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases Corporate Presentation BioCardia, Inc. (NASDAQ: BCDA) Peter Altman, PhD President and CEO paltman@biocardia.com www.biocardia.com 05295-AU (MKT) Corporate Presentation September 2025 1
Slide 2: Presentation Content and Disclaimer
Presentation Content and Disclaimer Presentation Content No part of this presentation or the information herein may be reproduced, photocopied, redistributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose without the consent of BioCardia
Slide 3: Executive Summary
Executive Summary Late-Stage Cell and Cell Derived Biotherapeutics for Cardiac and Pulmonary Diseases • CardiAMP® cell therapy for ischemic heart failure with TAM of > $17.5 Billion in USA1. • Granted FDA breakthrough designation and CMS reimbursement at $17,500 per procedure in place. • CardiAMP-HF
Slide 4: Problem: Heart failure, a disease with enormous unmet need
Problem: Heart failure, a disease with enormous unmet need • Affects more than 56.2 million people worldwide 1, with 50% mortality at five years 2. • No existing therapies are curative, they currently only slow disease progression. • Recent data shows newer meds only reduce mortality by 0.6%/year (s
Slide 5: Current Options for Patients - Expensive, Unable to Heal Failing Hearts
Current Options for Patients - Expensive, Unable to Heal Failing Hearts Demonstrating a reduction in mortality without replacing the heart remains a challenge in heart failure. Class I, II. & III Class III Class IV Medications Devices Hemodynamic Transplantation (Tx) Beta-Blockers CRT & CRT-D Su
Slide 6: Developing solutions: Therapeutic Product Pipeline
Developing solutions: Therapeutic Product Pipeline Autologous and allogeneic cells for cardiac and pulmonary disease Supported by best-in-class interventional biotherapeutic delivery. Therapeutic Platform Candidate Preclinical Phase 1 Phase 2 Phase 3 Autologous Mononuclear Cells CardiAMP® HF Ischemi
Slide 7: Biotherapeutic Delivery: Helix, Morph, and Heart3D
Biotherapeutic Delivery: Helix , Morph®, and Heart3D Empowering a seamless transition from bench to commercialization for partners. Partners: 05295-AU (MKT) Corporate Presentation September 2025 7
Slide 8: Potential Solution: CardiAMP Cell Therapy
Potential Solution: CardiAMP Cell Therapy For ischemic HFrEF (BCDA-01) FDA CBER regulated as device system. Medicare reimbursement established for two pivotal trials. 05295-AU (MKT) Corporate Presentation September 2025 8
Slide 9: CardiAMP Cell Therapy Mechanism of Action
CardiAMP Cell Therapy Mechanism of Action Pre therapy Post therapy 2X Increased Capillary Density 80% Decreased Fibrosis Silva et al. Tex Heart Inst J (2011);38(3):219-24. Takahashi, M. et al. (2006) Am J Physiol Heart Circ 291:H886-H893. 05295-AU (MKT) Corporate Presentation September 2025 9
Slide 10: CardiAMP Cell Therapy is a Significant Advance
CardiAMP Cell Therapy is a Significant Advance The 1st cardiac cell therapy that combines a pre-procedural assay, point of care cell processing system and transendocardial delivery system. How is it unique from other cardiac cell therapies? Precision Medicine Dx High Dose Efficient Delivery Autologo
Slide 11: CardiAMP HF Current Status
CardiAMP HF Current Status FDA Breakthrough Device Designation granted based on results from trials to date. CMS Reimbursement Code C9782 for CardiAMP Cell Therapy for both treated and control patients for Calendar Year (CY) 2025, is assigned to APC 1590 (New Technology – Level 39: $15,001–$20,000)
Slide 12: CardiAMP HF approval is being sought based on this data
CardiAMP HF approval is being sought based on this data CardiAMP HF Top Manuscript Potential CardiAMP HF 2025 2026 FDA/ Japan PMDA Meetings submission in Japan and USA CardiAMP HF II Enrolling CardiAMP HF II enrolling Japan approval pathway may have greater potential for near-term approval as we b
Slide 13: Design of CardiAMP HF II Confirmatory Trial
Design of CardiAMP HF II Confirmatory Trial FDA Approved protocol for up to 250 patients at up to 40 centers Focused on NYHA II and III ischemic HFrEF with NTproBNP >500 pg/ml Primary endpoint is Finkelstein Schoenfeld composite of heart death, major adverse cardiac and cerebrovascular events,
Slide 14: CardiAMP Cell Therapy 2nd Indication: Chronic Myocardial Ischemia with Refractory Angina
CardiAMP Cell Therapy 2nd Indication Chronic Myocardial Ischemia with Refractory Angina 05295-AU (MKT) Corporate Presentation September 2025 14
Slide 15: CardiAMP Cells in Chronic Myocardial Ischemia Trial (BCDA-02)
CardiAMP Cells in Chronic Myocardial Ischemia Trial (BCDA-02) NCT03455725, IDE Trial for Premarket Approval Burden of Illness and Unmet Need Characterized by severe chest pain. Patients suffer from poor perceived health status and psychological distress, have significant impairment in quality of
Slide 16: CardiAMP Cells in Chronic Myocardial Ischemia Trial: Roll-in Cohort Clinical Results
CardiAMP Cells in Chronic Myocardial Ischemia Trial (BCDA-02) Roll-in Cohort Clinical Results Early results are compelling for both improved angina episode reduction and increase in exercise tolerance time (ETT) which has only been shown with cell therapy. Last open label roll-in cohort patient reac
Slide 17: CardiALLO Cell Therapy 2nd Therapeutic Platform Ischemic Heart Failure
CardiALLO Cell Therapy 2nd Therapeutic Platform Ischemic Heart Failure 05295-AU (MKT) Corporate Presentation September 2025 17
Slide 18: Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) CardiALLO MSC
Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) CardiALLO MSC “Off the shelf” cell therapy based on cells from a single donor to treat many patients, using the same delivery system as CardiAMP programs. Has advantages for patients who do not qualify for CardiAMP because of their cel
Slide 19: Phase I/II TRIDENT Clinical Study, NCT02013674
Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) Phase I/II TRIDENT Clinical Study, NCT02013674 Allogeneic MSC at 20M and 100M cells (N= 30) delivered at ten sites with Helix. Primary outcome measures: thirty-day post catheterization incidence of predefined treatment-emergent serious adv
Slide 20: CardiALLO MSC, NCT05925608, IND Phase I/II
Allogeneic Mesenchymal Stem Cells in Heart Failure (BCDA-03) CardiALLO MSC, NCT05925608, IND Phase I/II Trial Design: The clinical trial will be testing prospectively an optimized Open Label Roll-in: 3X3 Dose dosage and delivery of allogeneic MSC in patients with Escalations (N=9) ischemic inflammat
Slide 21: Intellectual Property, Team, Finance, Catalysts
Intellectual Property Team Finance Catalysts 05295-AU (MKT) Corporate Presentation September 2025 21
Slide 22: Intellectual Property Overview
Intellectual Property Overview Exclusive rights to over 60 patents and patent applications in USA, Europe, China, India, and Japan with goal to protect the company’s platform and therapeutic initiatives. 05295-AU (MKT) Corporate Presentation September 2025 22
Slide 23: Executive Management Team
Executive Management Team Board of Directors: Andrew Blank, Chairman of the Board, CEO Archive America, Board Member Neumentum Jay Moyes, Chairman Audit Committee, Board Member Puma Biotechnology, Inc. Simon Stertzer, M.D., Professor of Medicine Cardiology Emeritus, Stanford Richard Krasno,
Slide 24: Selected Financial Data
Selected Financial Data Year Year Year Year Ended Ended Ended Ended 31-Dec-24 31-Dec-23 31-Dec-22 31-Dec-21 ($mm) ($ mm) ($ mm) ($ mm) Revenues $0.06 $0.5 $1.4 $1.0 Net Loss $7.9 $11.6 $11.9 $12.6 Cash used in $8.0 $10.0 $10.6 $10.4 operations Cash & Equivalents $2.4 $1.1 $7.4 $12.9 Debt N/A N/A N/A
Slide 25: Anticipated Catalysts
Anticipated Catalysts BCDA-01 CardiAMP Autologous Cell Therapy in Heart Failure (HF) Japan PMDA meetings on approvability based on subgroup analysis and safety~Q4 2025. This could enable submission for approval in 2026. USA FDA meetings on approvability based on subgroup analysis and safety~Q4 2
Slide 26: Back up slides: CardiAMP HF data slides
Back up slides: CardiAMP HF data slides presented at 26 05295-AU (MKT) Corporate Presentation September 2025
Slide 27: CardiAMP Heart Failure and CardiAMP HF II Trial Executive Steering Committee
CardiAMP Heart Failure and CardiAMP HF II Trial Executive Steering Committee Dr. Carl Pepine, University of Florida Professor of Medicine, Division of Cardiovascular Medicine, co-director of CTSI Multi-site Study Support Team at the National Center for Research, has been on the editorial boards of
Slide 28: MACE-Free Survival
MACE-Free Survival nEvents A – 15/74 (20.3%) nEvents C – 13/41 (31.7%) P =0.17 p-value = 0.170 number at risk 05993-C (CLIN) CardiAMP HF Trial CSR 2025 07 20 05295-AU (MKT) Corporate Presentation September 2025 28
Slide 29: Major Adverse Cardiovascular Events (MACE)
Major Adverse Cardiovascular Events (MACE) Treatment Control All MACE All-cause death, LVAD, Heart… All-cause death Heart transplant LVAD Nonfatal MACE Hospitalization for progression of… Myocardial Infarction Stroke 0% 5% 10% 15% 20% 25% 30% 35% 05295-AU (MKT) Corporate Presentation September 2025
Slide 30: Primary and secondary efficacy measures
Primary and secondary efficacy measures Active Treatment Control P-value (N=74) (N=41) Primary effectiveness outcome: hierarchical composite of all- cause death, LVAD or cardiac transplantation, non-fatal HFHs, WR = 1.01 0.939 MI, stroke and change in 6MWD from baseline through 24 months Secondary e
Slide 31: Subgroup Analysis
Subgroup Analysis 05993-C (CLIN) CardiAMP HF Trial CSR 2025 07 20 05295-AU (MKT) Corporate Presentation September 2025 31
Slide 32: Primary and secondary efficacy measures NTproBNP>500pg/ml
Primary and secondary efficacy measures NTproBNP>500pg/ml Active Treatment Control P-value (N=35) (N=22) Primary effectiveness outcome: hierarchical composite of all-cause death, LVAD or cardiac WR = 1.61 0.07 transplantation, non-fatal HFHs, MI, stroke and change in 6MWD from baseline through 24 mo
Slide 33: Primary and secondary efficacy measures NTproBNP>500pg/ml
Primary and secondary efficacy measures NTproBNP>500pg/ml Active Treatment Control (n=35) (n=22) 770 Patient Pairs Active Treatment Wins Control Wins Tier 1 193 (25%) 492 Ties (64%) 85 (11%) Tier 2 103 (13%) 333 Ties (43%) 56 (7%) Tier 3: MLHFQ 168 (22%) 78 Ties (10%) 87 (11%) Tier 3: 6MWT 147 (19%)
Slide 34: Covariate Analysis for NTproBNP > 500pg/ml
Covariate Analysis for NTproBNP > 500pg/ml 05295-AU (MKT) Corporate Presentation September 2025 34
Slide 35: CardiAMP HF Trial Results
CardiAMP HF Trial Results CONCLUSIONS: Intramyocardial delivery of autologous mononuclear cells for patients with ischemic HFrEF is safe but the primary efficacy 3- tier composite outcome was not met using six-minute walk distance test at tier 3, due to improved 6MWD in both groups. Significant clin